AFT new FDA approval could be a shot in the arm

AFT new FDA approval could be a shot in the arm
Analyst sentiment is positive after FDA approval of Maxigesic IV. (Image: Hyloris Pharmaceuticals)
Ben Moore
AFT Pharmaceuticals had a bump in share price on Wednesday morning following approval of its intravenous post-operative pain relief drug by the United States Food and Drug Administration.Following the announcement of the approval of Maxigesic IV, which came in overnight, the stock lifted 16 cents per share to $3.56 at the open on the New Zealand stock exchange (NZX), up from $3.40 at yesterday's close. It has since dipped to $3.50.AFT co-founder and managing director Hartley Atkinson said they were delighted to receive the second appro...

More Markets

Five reasons gold is surging toward US$5,000 an ounce
Markets

Five reasons gold is surging toward US$5,000 an ounce

Buying the precious metal has become the antidote for market jitters.

NZ sharemarket ends week down almost 2%
Markets Market Close

NZ sharemarket ends week down almost 2%

The S&P/NZX 50 Index closed at 13,448.24, down 108.63 points or 0.8%.

Graham Skellern 23 Jan 2026
Mainland Group sale expected to settle in the first quarter
Primary Sector

Mainland Group sale expected to settle in the first quarter

The Fonterra deal had been tipped to go through in the first half of this year.

Riley Kennedy 23 Jan 2026
Increased Chinese marriages, more babies expected
Primary Sector

Increased Chinese marriages, more babies expected

The birth rate in the People's Republic of China fell to a record low.

Riley Kennedy 23 Jan 2026